Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
Location: United States
Employees: 51-200
Total raised: $871M
Founded date: 2019
Investors 4
| Date | Name | Website |
| 07.06.2024 | Koch Disru... | kochdisrup... |
| - | 8VC | 8vc.com |
| 27.10.2020 | Eclipse Ve... | eclipse.vc |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 15.06.2026 | Series D | $277M | ARK Invest... |
| 29.01.2026 | Series D | $257M | EDBI |
| 23.08.2023 | Series C | $255M | - |
| 05.05.2021 | Series B | $82M | Eclipse Ve... |
Mentions in press and media 38
| Date | Title | Description |
| 29.06.2026 | Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities | Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot program, CNBC has learned. The FDA PreCheck program is designed t... |
| 16.06.2026 | Vinyl Equity Secures $20M to Revolutionize Capital Markets Infrastructure | Vinyl Equity, a fintech innovator, has raised $20 million in Series A funding. Jump Capital led the round. The company modernizes capital markets infrastructure. It replaces outdated, manual systems. Vinyl offers a digital platform. This pl... |
| 16.06.2026 | Cellares Secures $327M, Revolutionizing Cell Therapy Manufacturing Globally | Cellares closed its Series D funding at $327 million, backed by ARK Invest, Prime Radiant Partners, and other major investors. This capital drives global expansion of its automated cell therapy manufacturing. The IDMO model and Smart Factor... |
| 15.06.2026 | Podium Automation Raises $18M in Series A Funding | Podium Automation, a NYC-based control panel manufacturer, raised $18M in Series A funding. The round was led by Construct Capital, with participation from Andreessen Horowitz, Transition Ventures, Sunflower Capital, and Banter Capital. The... |
| 15.06.2026 | Cellares Expands Series D To $327 Million With $50 Million Investment From Prime Radiant Partners | Cellares announced that Prime Radiant Partners has invested $50 million in the company’s Series D financing, bringing the total round to $327 million and providing additional capital to support commercial operations, a planned initial publi... |
| 15.06.2026 | Cellares Raises $50M in Series D Funding | Cellares, a South San Francisco, CA-based Integrated Development and Manufacturing Organization (IDMO) which specializes in cell therapies, raised an additional $50M in Series D funding. Prime Radiant Partners’ Prime Radiant Fund SLP SICAV-... |
| 09.06.2026 | Vinyl Equity Raises $20M in Series A Funding | Vinyl Equity, a Chicago, IL-based financial technology infrastructure company for capital markets and corporate transactions and SEC-registered transfer agent, raised $20M in Series A funding. The round was led by Jump Capital, with partici... |
| 09.06.2026 | Cellares Raises $277 Million Series D As ARK Invest Joins Funding Round | Cellares announced that ARK Invest has joined its Series D financing with a $20 million investment, bringing the total round to $277 million. The funding round includes a number of major institutional investors across public and private mar... |
| 09.06.2026 | Cellares Receives $20M Investment from ARK Invest | Cellares, a South San Francisco, CA-based Integrated Development and Manufacturing Organization (IDMO), received a $20m investment from ARK Invest. ARK Invest joined the company’s Series D financing, bringing the total Series D to $277m. AR... |
| 30.01.2026 | Cellares Secures $257M to Industrialize Cell Therapy Manufacturing | Cellares, a leading Integrated Development and Manufacturing Organization (IDMO), just secured $257 million in Series D funding. This pivotal round, co-led by investment giants BlackRock and Eclipse, elevates Cellares' total capital to an i... |
Show more